TABLE 1.
Patients’ demographic characteristics.
| Characteristics | Value a (n = 20) |
|---|---|
| Age (year) | 60.5 (18–92) |
| Gender | |
| Male, % | 12 (60%) |
| Female, % | 8 (40%) |
| Total body weight (kg) | 55 (45–65) |
| Daily dose b | |
| 2.0 MU, % | 4 (20%) |
| 1.5 MU, % | 17 (85%) |
| 1.0 MU, % | 2 (10%) |
| Estimated CrCL (ml/min) | 48.8 (6.5–193.8) |
| ALT (U/L) | 37.5 (7–495) |
| ALB (g/L) | 30.8 (22.2–43.3) |
| APACHE II score | 21.5 (8–34) |
| SOFA score | 8 (3–18) |
| Continuous renal replacement c | 2 (10%) |
| Underlying disease | |
| Liver disease | 13 (65%) |
| Surgery | 10 (50%) |
| Chronic kidney disease | 8 (40%) |
| Sepsis | 8 (40%) |
| Solid organ transplantation | 4 (20%) |
| Site of infection | |
| Pulmonary | 16 (80%) |
| Bloodstream | 6 (30%) |
| Urinary tract | 3 (15%) |
| Abdomen | 2 (10%) |
| Pathogenic bacteria cultures | |
| A. baumannii | 10 (50%) |
| K. pneumoniae | 6 (30%) |
| P. aeruginosa | 2 (10%) |
| None | 4 (20%) |
| Concomitant antibiotic(s) | |
| Meropenem | 16 (80%) |
| Ceftazidime/avibactam | 3 (15%) |
| Piperacillin/tazobactam | 2 (10%) |
| Cefoperazone/sulbactam | 2 (10%) |
| Linezolid | 2 (10%) |
| Teicoplanin | 2 (10%) |
a
Values are median (range) or No. (%);
b
Dosage regimens were adjusted in three patients;
c
The interval between CRRT, and blood samples collection was over 72 h in 2 patients. MU, million units; CrCL, creatinine clearance estimated by the Cockcroft-Gault equation; ALT, alanine aminotransferase; ALB, albumin; APACHE II, acute physiology and chronic health evaluation II; SOFA, sequential organ failure assessment.